Guggenheim Raises Regeneron Price Target to $975, Oppenheimer Lifts to $865
RBC Capital reiterated a Hold rating on Regeneron with a $745 target, while Guggenheim raised its price objective to $975 from $865 and Oppenheimer lifted its to $865 from $750. Analysts cited fianlimab/Libtayo LAG-3 melanoma data, a Q2 FDA decision on the Eylea HD syringe and Q1 NDA for cemdisiran.
1. Analyst Price Target Updates
RBC Capital maintained its Hold rating on Regeneron with a $745 price target. Guggenheim upgraded to a Buy rating and boosted its target to $975 from $865, while Oppenheimer kept an Outperform rating and raised its objective to $865 from $750.
2. Upcoming Clinical and Regulatory Catalysts
Analysts identified three key near-term events: fianlimab/Libtayo LAG-3 trial data in melanoma, an FDA decision on the Eylea HD syringe scheduled for Q2 and a Q1 NDA filing for cemdisiran in generalized myasthenia gravis.